The chairman of Swiss drugmaker Novartis expects Alcon to be valued at between $20 billion and $30 billion when the opthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft.
“Just how much it’s ultimately going to be will be determined when we know how debt and other things will be quantified,” Joerg Reinhardt told the Swiss financial newspaper.
Novartis announced on Friday it is spinning off the eye care surgical equipment and contact lens unit, with $7 billion in annual revenue. The business no longer fits the drugmaker’s strategy of focusing on prescription medicines, Novartis concluded.
The Basel-based company will also repurchase up to $5 billion in shares through the end of next year.
Reinhardt said it was hard to determine whether Alcon, bought over time for $52 billion from Nestle in a deal concluded in 2011, ever really earned money for Novartis.
“Tough to say, since Alcon had to be revamped multiple times,” he said. “But I would say, all things considered, we didn’t lose money on Alcon.”
Reinhardt also said there were no changes to Novartis’s roughly $13 billion stake in Roche (ROG.S). His company has, for now, abandoned active plans to unload the package, and Reinhardt has returned to calling it “a financial investment with a certain strategic component.”
By John Miller
Source: Reuters
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.
